Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Samuel Hague"'
Autor:
Giles Dixon, Samuel Hague, Sarah Mulholland, Huzaifa Adamali, Aye Myat Noe Khin, Hannah Thould, Roisin Connon, Paul Minnis, Eoin Murtagh, Fasihul Khan, Sameen Toor, Alexandra Lawrence, Marium Naqvi, Alex West, Robina K. Coker, Katie Ward, Leda Yazbeck, Simon Hart, Theresa Garfoot, Kate Newman, Pilar Rivera-Ortega, Lachlan Stranks, Paul Beirne, Jessica Bradley, Catherine Rowan, Sarah Agnew, Mahin Ahmad, Lisa G. Spencer, Joshua Aigbirior, Ahmed Fahim, Andrew M. Wilson, Elizabeth Butcher, Sy Giin Chong, Gauri Saini, Sabrina Zulfikar, Felix Chua, Peter M. George, Maria Kokosi, Vasileios Kouranos, Philip Molyneaux, Elisabetta Renzoni, Benedetta Vitri, Athol U. Wells, Lisa M. Nicol, Stephen Bianchi, Raman Kular, HuaJian Liu, Alexander John, Sarah Barth, Melissa Wickremasinghe, Ian A. Forrest, Ian Grimes, A. John Simpson, Sophie V. Fletcher, Mark G. Jones, Emma Kinsella, Jennifer Naftel, Nicola Wood, Jodie Chalmers, Anjali Crawshaw, Louise E. Crowley, Davinder Dosanjh, Christopher C. Huntley, Gareth I. Walters, Timothy Gatheral, Catherine Plum, Shiva Bikmalla, Raja Muthusami, Helen Stone, Jonathan C.L. Rodrigues, Krasimira Tsaneva-Atanasova, Chris J. Scotton, Michael A. Gibbons, Shaney L. Barratt
Publikováno v:
ERJ Open Research, Vol 10, Iss 1 (2024)
Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in
Externí odkaz:
https://doaj.org/article/de9c81f7baad42d39a03dbc60d9a1955
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:835-840
Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients wit
Publikováno v:
Blood. 138:4566-4566
Introduction: Gemcitabine, Dexamethasone, and Cisplatin or Carboplatin (GDP/GDCarboP) regimen has comparable efficacy to other salvage therapy in relapsed/refractory (R/R) aggressive lymphoma with successful stem cell mobilisation and bridge to autol